OnsiteGene has unveiled myNAT, a handheld, battery-powered real-time PCR instrument capable of 40-cycle runs in under 10 minutes, with a target cost of under $5 per test, according to the company.
Myriad Genetics has launched the FirstGene Multiple Prenatal Screen, a test that combines four prenatal genetic screens from a single blood draw as early as eight weeks gestation, according to the company.
Bio-Rad has launched Vericheck ddPCR kits for quality control in cell and gene therapy manufacturing, offering validated workflows for mycoplasma detection, capsid analysis, and residual DNA quantification.
The new technologies address library normalization and amplification accuracy for high-throughput and oncology sequencing.
Read More
The whole-genome sequencing assay is now available for breast, colorectal, and renal cancers following new clinical study results.
Read More
The NCCN has updated its bladder cancer guidelines to include FDA-approved ctDNA-based MRD testing for post-surgical risk assessment and adjuvant immunotherapy decisions in muscle-invasive bladder cancer.
Read More
The point-of-care assay provides results in 15 minutes and received a waiver for use in decentralized settings.
Read More
A study reports that an OpenAI reasoning model improved rare disease diagnostic yield by 4.8% in previously unsolved cases, offering new leads after specialist analysis.
Read More
The Fleming Initiative and Cepheid have launched a 30-month study in England to compare rapid molecular and traditional culture screening for drug-resistant carbapenemase-producing Enterobacterales in hospital settings.
Read More
A study reports that long-read genome sequencing can replace up to 15 separate tests and improve diagnostic yield for rare genetic disorders, according to researchers in the Netherlands.
Read More
The NCCN has updated its guidelines to recommend cerebrospinal fluid-based molecular profiling for inoperable high-grade gliomas and glioblastomas, expanding indications for liquid biopsy in CNS cancer care.
Read More
The system uses routine blood draws to provide results in 17 minutes, offering an alternative to invasive diagnostic methods.
Read More
New updates include expanded capabilities for microbial identification and advancements in sepsis diagnostics and sequencing workflows.
Read More
An experimental assay detected residual HPV-related cancer DNA after surgery and was associated with poorer outcomes in an observational study.
Read More
The system simultaneously detects RSV, influenza A and B, and SARS-CoV-2 from a nasal swab in under 10 minutes.
Read More
Guardant360 CDx can now identify patients eligible for zongertinib, the first targeted therapy approved as an initial treatment option for HER2-mutant advanced non-small cell lung cancer.
Read More
Mayo Clinic and Stanford Medicine researchers have developed a liquid biopsy that profiles tumor microenvironments to help predict immunotherapy response, according to a study published in Nature.
Read More
The PTC Harmony 96 and PTC Harmony Deepwell systems are designed to provide high-performance PCR for academic and biopharma laboratories.
Read More